Vor Biopharma (VOR) Common Equity (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Common Equity data on file, last reported at -$150.4 million in Q1 2026.

• On a quarterly basis, Common Equity fell 327.68% year-over-year to -$150.4 million in Q1 2026; TTM through Mar 2026 was -$150.4 million, a 327.68% decrease from a year earlier, with the FY2025 full-year figure at -$164.3 million, down 69.98% from the prior year.
• Common Equity for Q1 2026 stood at -$150.4 million, up from -$164.3 million in the prior quarter.
• Over the last five years, Common Equity for VOR reached as high as $250.6 million in Q4 2022 and fell as low as -$2.2 billion in Q3 2025.
• Historically, Common Equity has averaged -$132.0 million across 5 years, with a median of $123.0 million in 2024.
• Across the five-year window, Common Equity advanced 18.39% in 2023 and sank 3150.49% in 2025, its largest moves.
• Year by year, Common Equity stood at $250.6 million in 2022, then plunged by 39.86% to $150.7 million in 2023, then plunged by 164.13% to -$96.7 million in 2024, then sank by 69.98% to -$164.3 million in 2025, then rose by 8.45% to -$150.4 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were -$150.4 million in Q1 2026, -$164.3 million in Q4 2025, and -$2.2 billion in Q3 2025.